Uncategorized

New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies

Genentech, a member of the Roche Group, announced data from Stage 1 of the National Institutes of Health -sponsored pivotal Phase III OUtMATCH study evaluating the efficacy and safety of Xolair® in patients allergic to peanuts and at least two other common foods were published in the New England Journal of Medicine and featured in

New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies Read More »

Scroll to Top